Reference

Last reviewed: 28 Apr 2026
Sources cited: 13
Residues: 15

Open Vial Plan→

Primary structure15 residues · 1,419.5 Da

01GlyGlycine

02GluGlutamate

03ProProline

04ProProline

05ProProline

06GlyGlycine

07LysLysine

08ProProline

09AlaAlanine

10AspAspartate

11AspAspartate

12AlaAlanine

13GlyGlycine

14LeuLeucine

15ValValine

Nonpolar Polar Acidic Basic Aromatic Gly/Pro

BPC-157

Last verified: 2026-04-23

At a glance


Also known as	Body Protection Compound 157, pentadecapeptide BPC 157, PL 14736
Class	Synthetic pentadecapeptide derived from a gastric protective protein
Typical route	Subcutaneous injection, intramuscular injection, oral (capsule/liquid), sublingual
Half-life	~15 minutes (rat IV); ~5 minutes (dog IV). Human PK is essentially unpublished.
Molecular weight	1,419.5 Da
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)

What it is

BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid fragment of a larger gastric protective protein originally isolated from human stomach lining. It is unusual among peptides for being orally stable: it survives stomach acid and digestive enzymes, which is why oral and sublingual protocols are viable at all. Most other peptides are destroyed in the gut and must be injected.

It is marketed and used primarily as a healing and recovery agent — for tendon, ligament, gut, and soft tissue injury. It is not an approved medicine anywhere in the world.

Mechanism

BPC-157 appears to work primarily through promoting angiogenesis (new blood vessel formation) in injured tissue. The best-characterised pathway is activation of vascular endothelial growth factor receptor 2 (VEGFR2), which in turn activates the Akt–endothelial nitric oxide synthase (eNOS) axis to produce nitric oxide. A second, VEGF-independent pathway via Src–caveolin-1–eNOS has also been identified.1 2

The 2025 Sikirić commentary emphasises that BPC-157’s nitric-oxide effects appear self-limiting — increases or decreases in NO are paired with free-radical counter-regulation, which the authors argue distinguishes it from exogenous VEGF administration (which can trigger pathological vessel formation).2 This is a mechanistic argument from the peptide’s primary research group; independent confirmation in humans is limited.

Additional proposed mechanisms include modulation of the FAK–paxillin cell migration pathway, dopamine and serotonin system effects, and gut barrier restoration. These are largely rodent-model findings.

Routes of administration

BPC-157 is unusual in being viable across four meaningfully different routes. The choice is not cosmetic — routes differ in bioavailability, onset, side effect profile, and best-fit use-case.

Subcutaneous (subQ) injection


Bioavailability	~14–19% (rat IM data; human data essentially absent)
Onset	Minutes (plasma); therapeutic effect cumulative over days to weeks
Duration	Plasma clearance under 30 min; biological effect persists via downstream repair processes
Typical dose (this route)	250–500 mcg, 1–2× daily
Equipment	Insulin syringe (U-100), BAC water, alcohol wipes, sharps bin
When this route makes sense	Systemic healing, tendon/ligament/joint injury, highest-confidence dosing, research-grade precision

The community default. Injection site is often near an injury for local tendon/ligament work, or systemic subQ (abdomen, thigh) for general repair. Rotate sites to avoid local irritation. Most of the published animal literature uses injected routes, so this is where the evidence base is strongest — though “strongest” is relative given thin human data overall.

Intramuscular (IM) injection


Bioavailability	45–51% (beagle dog data); significantly higher than subQ
Onset	Minutes (plasma)
Duration	Same short plasma curve
Typical dose (this route)	250–500 mcg — same range as subQ despite higher bioavailability (conservative community practice)
Equipment	Longer needle (0.5–1 inch), IM injection into muscle belly
When this route makes sense	Deep muscle injury, local delivery to an injured muscle group

Less commonly used in the community. IM is more painful than subQ, requires longer needles, and most users don’t find the bioavailability advantage compelling versus the ease of subQ. Occasional reports of IM delivery directly to an injury site (e.g. quadriceps strain) to concentrate local effect.

Oral (capsule or liquid)


Bioavailability	Modest — limited by gut absorption despite GI stability. Actual human oral bioavailability is not formally characterised.
Onset	30–90 minutes for systemic effect; local gut effect likely much faster
Duration	Likely similar plasma profile to injected; chronic dosing is standard
Typical dose (this route)	250–500 mcg/day (often split AM/PM); up to 1,000 mcg/day reported for acute gut contexts
Equipment	None — pre-made capsules or oral drops
When this route makes sense	Gut-focused protocols (IBS, leaky gut, reflux, ulcers), needle-averse users, maintenance dosing

BPC-157 is genuinely unusual among peptides for being GI-stable — it survives stomach acid and digestive enzymes, which is why oral works at all. For gut-targeted conditions this is arguably the preferred route because the compound acts locally before systemic absorption matters. Commonly taken 30–60 min before a meal or 2+ hours after, on an empty stomach. Practical note: oral product potency is largely unverifiable by the user, so purity/dose confidence is lower than injectables from the same supplier.

Sublingual (under the tongue)


Bioavailability	Hypothesised to be higher than swallowed oral (bypasses first-pass hepatic metabolism) but not formally characterised in BPC-157
Onset	15–45 minutes
Duration	Similar to oral
Typical dose (this route)	250–500 mcg/day, usually split into two doses
Equipment	Liquid drops, held under tongue 60–90 seconds before swallowing
When this route makes sense	Middle ground between oral (convenient) and injection (higher bioavailability); gut-focused users who want faster systemic effect

Mechanism-wise plausible but under-researched. Community reports suggest sublingual users typically report faster-onset subjective effects than swallowed oral, but the evidence for meaningfully higher bioavailability is weak. Suppliers increasingly sell pre-made sublingual drops, which is driving adoption.

Cross-route comparison

Doses do not translate 1:1 across routes. A 250 mcg subQ dose and a 250 mcg oral dose reach different plasma levels by meaningfully different paths. The community has converged on similar nominal doses across routes (250–500 mcg) because the bioavailability differences are partly offset by different distribution patterns, but this is pragmatic convention, not pharmacology.

Route selection guidance:

Gut, reflux, IBS, leaky gut → oral or sublingual (local effect, targeting site of action)
Tendon, ligament, joint injury → subQ, near the injury where feasible
Deep muscle injury → IM, directly to the muscle belly
Systemic recovery, anti-inflammatory → subQ for highest-confidence dosing; oral for maintenance
Needle-averse or travel use → oral

What the evidence says

Honest summary: the evidence base is overwhelmingly preclinical.

Human trials:

One Phase I trial (NCT02637284, 2015) — 42 healthy volunteers, safety and PK. Study is listed as cancelled; results were never published. This is the most cited gap in the evidence base.3
2025 Lee & Burgess pilot (IV, n=2) — healthy adults received IV BPC-157 up to 20 mg. Well tolerated, no adverse effects, no changes to cardiac/hepatic/renal/thyroid/metabolic markers. Plasma returned to baseline within 24 hours. Sample size is 2.4
Retrospective knee-pain case series — intraarticular BPC-157 for chronic knee pain, 7 of 12 patients reported >6 months relief.5
Early 2000s Croatian trials — reportedly examined BPC-157 for inflammatory bowel disease. Published details are sparse and not widely available in English.

That is the complete human evidence base as of April 2026.

Rodent and in-vitro evidence is extensive. Studies document effects on tendon/ligament healing, gut ulcers, traumatic brain injury, cardiac injury, nerve regeneration, and more. The recurring pattern: strong effect sizes in animal models, no human replication.

Community evidence is voluminous but observational. Reddit, Discord, and podcast anecdotes describe tendon injury recovery, gut symptom relief, joint pain reduction. This is what users report. It is not clinical evidence.

Typical use patterns

What users and published protocols report. Observations, not recommendations.

Subcutaneous / intramuscular:

250–500 mcg per dose, once or twice daily
Typical cycle: 4–8 weeks on, then a break
Injection site often near the injury (e.g. local subQ near an injured tendon), though systemic subQ (abdomen) is also common
Community reports: 500 mcg twice daily during acute injury phase, tapering to 250 mcg daily for maintenance

Oral / sublingual:

250–500 mcg/day, often split into two doses (morning and evening)
Up to 1,000 mcg/day reported for acute contexts (gut inflammation, IBS flares)
Commonly taken on an empty stomach — 30–60 min before a meal or 2+ hours after
Sublingual routes typically hold the liquid under the tongue for 60–90 seconds
Anecdotally preferred for gut-focused protocols (IBS, leaky gut, reflux, ulcers) since the compound is naturally stable in the GI tract

Stacking:

Most commonly paired with TB-500 for systemic healing (the “BPC + TB” stack)
Paired with KPV for gut-specific protocols
Often run alongside GHK-Cu topically for skin/wound contexts

For sensitive systems

If you have MCAS, histamine intolerance, UARS, POTS, long COVID, autoimmune conditions, ME/CFS, PMDD, or a generally hyperreactive immune/nervous system, standard BPC-157 protocols are not calibrated for you. This does not mean you can’t use it — many in this population report benefit over weeks — but the introduction needs to be different.

Start dose. 50–100 mcg/day is a reasonable introduction, roughly a quarter to half of community-standard. Oral/sublingual is often better tolerated than injection initially, since injection itself is a histamine trigger in reactive people.

Ramp. Hold the start dose for 7–14 days. Only consider increasing if baseline is stable and no new symptoms have emerged. Many sensitive users plateau at 100–250 mcg/day and do not need the full biohacker range.

Expected flare profile. The first 2–5 days commonly include one or more of: headache, watery eyes, flushing, fatigue, brain fog, GI upset, generalised inflammatory feeling. This is consistent with BPC-157’s angiogenic/repair activity provoking an already-hyperreactive mast-cell system. It typically resolves in 5–10 days as the body settles.

What’s not normal — and warrants stopping: breathing difficulty, significant chest symptoms, facial swelling, severe prolonged flushing beyond the first few days, or any reaction that escalates rather than resolves.

What to have on hand:

H1 antihistamine (cetirizine, loratadine, or fexofenadine)
H2 antihistamine (famotidine)
Electrolytes — BPC’s vasodilatory effects can worsen POTS-range symptoms
Optional: quercetin or stabilised vitamin C, both community-reported as gentle mast-cell stabilisers

Some sensitive users pre-load antihistamines for the first week. This is a reasonable strategy with the caveat that you won’t know if you would have reacted without them.

Stop criteria. Stop and reassess if: flare lasts beyond 2 weeks, any symptom is severe, flare escalates week-on-week, or any new symptom appears that doesn’t fit the expected profile. Reintroducing at half the previous start dose after a 2-week break is a reasonable second attempt.

Stacking note. KPV has a stronger anti-mast-cell profile and is reported (community level, not clinical) to smooth BPC-157 introduction for MCAS users. Pairing them from the start — or pre-loading KPV for 7–10 days before introducing BPC-157 — is a common approach in this population.

Known interactions worth considering:

Low Dose Naltrexone (LDN): commonly used in MCAS/autoimmune populations. No documented interaction, but both modulate immune function; introduce BPC separately from any LDN dose change.
Cromolyn sodium, ketotifen: mast cell stabilisers. Likely complementary rather than interacting, but layering multiple immune modulators at once is hard to interpret.
Beta-blockers: if used for POTS, BPC’s vasodilatory effect may compound dizziness initially.
SSRIs/SNRIs: no documented interaction, but sensitive users sometimes report medication sensitivity shifts when starting peptides.

Reasonable expectations

Onset. For most use-cases (gut, tendon, systemic inflammation), any perceived effects typically emerge across 1–4 weeks, not days. Day-1 or day-2 sensations are more likely adjustment symptoms than therapeutic effect. Tendon/ligament healing, where it occurs, is often reported on timescales of 4–8 weeks.

Response rate. Community and retrospective reports suggest meaningful benefit in roughly half of users for the core use-cases (tendon/soft tissue, gut inflammation). Strictly observational, uncontrolled, subject to selection bias — not trial data. Many users report no clear effect.

What the literature actually supports. Tendon/ligament healing in rodents: strong. Gut protective effects in rodents: strong. Human evidence: three small pilot studies, one cancelled Phase I, a handful of retrospective case series. If someone claims BPC-157 is “proven” to do anything in humans, they are overreaching.

What not to expect.

Reversing structural joint damage (chondral, advanced OA, complete tendon tears)
Meaningful effects on neurological disease (ALS, Parkinson’s, MS) — rodent signals only, heavily over-extrapolated online
Performance enhancement in healthy tissue — this is not what the compound does
Rapid or dramatic change — BPC-157 is reported as gradual and cumulative, not acute

Cost

Approximate as of April 2026, research-chemical market. Vendor-neutral.


5 mg vial (injectable, lyophilised)	£20–45
10 mg vial	£35–70
Oral capsules (typical: 500 mcg × 60)	£40–80 per bottle
Cost per month, community-standard (500 mcg/day subQ)	~£30–50
Cost per month, sensitive-start (100 mcg/day subQ)	~£10–15
Cost per month, oral 500 mcg/day	~£40–80

Bulk purchasing (multiple vials) typically reduces unit cost by 20–30%. For a typical 6–8 week protocol at 250–500 mcg/day, 2–3 vials of 5 mg is usually sufficient. Oral is substantially more expensive per dose than injectable.

Reconstitution

Typical vial sizes available from research chemical suppliers: 2 mg, 5 mg, 10 mg.

Standard example (injectable):

5 mg vial + 2 mL bacteriostatic water → 2.5 mg/mL
250 mcg dose = 0.1 mL = 10 units on a U-100 insulin syringe

Oral/sublingual preparations are usually supplied as pre-made liquid drops or capsules; reconstitution from lyophilised powder for oral use is less common.

Open the Vial Plan calculator

Areas of concern ⚠

This compound has a vocal user base and a thin evidence base. Be clear-eyed.

Safety signals

No long-term human safety data exists. Zero. The longest prospective human study is a 2-person IV pilot; the cancelled 2015 Phase I trial would have been the first meaningful safety dataset and it was never completed.3 4
FDA has flagged unknown human toxicity and misuse potential as reasons for its regulatory posture.6

Adjustment period (first 1–2 weeks)

Users commonly report transient symptoms in the first days of a BPC-157 protocol that resolve as the body adapts. These are not well documented in peer-reviewed literature but are consistently reported across community sources and practitioners:10 11

Headache (estimated 10–20% of users in week 1) — plausibly linked to the peptide’s nitric-oxide-mediated vasodilation effect, which is part of the mechanism of action
Fatigue, lethargy, or mild brain fog — community reports attribute this to blood-pressure fluctuation during vasodilation
Mild nausea or GI changes (5–10%) — more common with oral/sublingual protocols
Occasional lightheadedness (3–7%) on standing, especially early in the protocol

What to do: symptoms typically resolve within 3–7 days. Adequate hydration is the most-cited mitigation. If symptoms are severe, persistent beyond 2 weeks, or escalate, stop and reassess.

Mast cell and histamine reactivity

This is under-discussed in the community and deserves specific attention for users with sensitive immune systems.

The evidence is mixed and genuinely interesting:

Preclinical (rodent) work from the peptide’s primary research group suggests BPC-157 suppresses mast cell activation in some anaphylactoid-reaction models — potentially better than antihistamines in those settings.12
Practitioner reports of using BPC-157 in mast cell activation syndrome (MCAS) patients describe a pattern of initial flares followed by improvement over weeks. Users experience watery eyes, headache, flushing, GI symptoms, or generalised inflammatory response in the first few days — then these resolve and downstream benefit emerges.13
The mechanistic explanation (not proven, but plausible): the compound’s angiogenic and repair activity mobilises tissue turnover, which itself triggers mast cell degranulation in reactive individuals. The peptide is not causing mast cell dysfunction — it’s provoking an already-hyperreactive system into an initial response.

What this means in practice:

Users with known MCAS, histamine intolerance, UARS, POTS, autoimmune conditions, long COVID, or a “reactive to everything” immune profile should approach BPC-157 with a different strategy than healthy biohackers
Start very low — a quarter or less of typical doses (e.g. 50–100 mcg rather than 250–500)
Expect possible initial flare. Headache, watery eyes, flushing, fatigue, GI upset in the first 2–5 days are not uncommon in this population
Have antihistamines available (H1 and H2; community commonly uses cetirizine + famotidine) and consider pre-loading
Stop and reassess if the flare is severe, includes breathing difficulty, or doesn’t improve within a week
Consider pairing with KPV, which has a stronger anti-inflammatory / anti-mast-cell profile and may smooth the introduction period (community pattern, not clinically established)13

This is an area where the standard “250–500 mcg daily” community protocols may be actively unsuitable.

Cancer / growth signalling concern (theoretical)

BPC-157 activates pro-migratory signalling (FAK–paxillin) and pro-angiogenic factors (VEGF, EGR-1, NO). These are the same pathways used by metastatic cancer cells to invade tissue and recruit blood supply.2 6
The peptide’s primary research group argues the effects are self-limiting and physiological rather than pathological, citing the paired free-radical counter-regulation.2
A 2017 colon-cancer rodent model actually showed BPC-157 reduced tumour growth by 45%. This is reassuring but is one study in one model.
Honest summary: no evidence BPC-157 causes cancer in humans. No evidence it doesn’t. Users with active cancer or recent cancer history should treat this as a contraindication until human data exists.

Quality and sourcing

BPC-157 is produced by unregulated research-chemical suppliers. Purity is not verified. Independent third-party testing is rare and when done, often shows variable peptide content, contamination, or incorrect sequence.
Counterfeit and under-dosed product is common — especially in oral/sublingual preparations where analysis is harder.
Storage matters: lyophilised BPC-157 is stable at room temperature but reconstituted solution should be refrigerated and used within ~30 days. Oral drops should be refrigerated.

Regulatory and sport

WADA has banned BPC-157 — prohibited in competition and out-of-competition for tested athletes.6
FDA currently classifies BPC-157 as an unapproved new drug (see FDA status section).
Possession is not criminal in most jurisdictions; prescribing, dispensing, and compounding are where the legal risk sits.

Measurement and dosing pitfalls

Doses are commonly expressed in micrograms (mcg) while vial contents are labelled in milligrams (mg). Unit confusion is the most common dosing error — a 1000× mistake is possible.
Reconstitution volumes vary widely across suppliers and protocols. Always recalculate units-per-dose after reconstitution, do not reuse a previous protocol’s volume assumption.
Oral product potency is largely unverifiable by the user — what’s on the label may not reflect what’s in the bottle.

Populations where caution is warranted

Pregnancy and breastfeeding — no data, default contraindication
Active or recent malignancy — theoretical concern around angiogenic/growth pathways
Retinopathy or other proliferative vascular conditions — theoretical, based on VEGF mechanism
Under 18 — no data, growth-pathway activation in developing tissue is a reasonable caution
Histamine-reactive and HPA-axis-dysregulated populations (MCAS, UARS, POTS, long COVID, autoimmune, histamine intolerance) — see “Mast cell and histamine reactivity” above. Not a contraindication, but a fundamentally different starting strategy (lower dose, slower ramp, antihistamine backup, stop criteria).

What the community often gets wrong

BPC-157 is often described as “healing anything” — the actual evidence is concentrated in tendon, ligament, gut, and soft tissue; effects on bone, cartilage, CNS, and cardiac tissue are extrapolated from rodent studies
Dose escalation (“more is better”) is common in forums; there is no human dose-response curve to support this
“It’s natural because it’s from the stomach” — BPC-157 is a synthetic fragment of a larger protein; the pentadecapeptide itself does not occur freely in the body

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Removed from 503A Category 2 (April 2026) — but not yet added to Category 1. Currently defaults to “unapproved new drug.” PCAC meeting 23–24 July 2026 will consider 503A Category 1 inclusion.	2026-04-23
UK (MHRA)	Not approved as a medicine. Not a controlled substance. Sale for human use is restricted; research-chemical sale is a regulatory grey area.	2026-04-23
EU (EMA)	Not approved. Similar posture to UK across most member states.	2026-04-23
WADA (sport)	Prohibited (in and out of competition)	2026-04-23

Narrative: The April 2026 update removed BPC-157 from the Category 2 (flagged safety risk) list because the original nominators withdrew their nominations. This is not an approval — it means the compound is no longer on either the restricted list or the approved list, defaulting to unapproved-new-drug status. The July 2026 PCAC meeting is the next meaningful regulatory event; inclusion on the 503A Category 1 list would open a legal compounding pathway through licensed pharmacies.7 8

What to track in Peptrax

BPC-157 is the compound where the gap between “took it for two weeks” and “actually decided whether it worked” is widest. Most users are treating a specific tendon, joint, or gut issue, and the honest read on whether it helped requires a baseline rating and a 4–6 week follow-up — not a vague impression. The signal worth capturing is the specific injury or symptom, rated weekly on the same scale, alongside whatever functional test matters (range of motion, pain on load, GI symptoms post-meal). Without that anchor, the compound becomes whatever the most recent good or bad day suggests.

For sensitive-systems users (MCAS, histamine intolerance, UARS, POTS), the higher-priority log is the first 1–2 weeks: any flushing, headache, GI flare, fatigue, or watery-eye reaction in the days after starting. The “initial flare then improvement” pattern reported in this population is real but only visible if you logged it as it happened. A clear written stop criterion before starting is more useful than reconstructing one mid-flare.

Across all users, route choice is editorial. SubQ at 250–500 mcg, oral 500 mcg/day, and sublingual drops are not interchangeable, and the “did this work” answer can be route-specific. Logging route, daily dose, and any concurrent compounds (KPV is the common pairing for sensitive-systems users; TB-500 for orthopaedic) makes the retrospective possible. Vial life and reconstitution dates matter because reconstituted BPC-157 should be used within ~30 days refrigerated.

For personal tracking and informational purposes only — not medical advice.